Back to Search

FOLD

Amicus Therapeutics, Inc
Data: 2026-04-24
$14.49
Price
0.21%
Change
$14.50
52W High
$5.51
52W Low
Buy/Sell Forecast Trendline Why Moving Charts Options

Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, the company is committed to advancing and expanding a pipeline of cutting-edge medicines for rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.

Quick Stats

59.7

AI Score

HOLD

1.67

Volume Ratio

Next Earnings

10

+ve Days (30d)

7

-ve Days (30d)

FOLD Stock Summary

Last updated

FOLD is currently trading at $14.49, positioned below its 200-day moving average of $, suggesting bearish momentum. The stock has a 52-week range of $5.51 to $14.5.

Technical Analysis: The 50-day moving average stands at $, which is above the current price, indicating bearish near-term pressure. The RSI (Relative Strength Index) reads , suggesting the stock is neutral with balanced momentum.

Money Flow Indicators: The Chaikin Money Flow (20-day) is , which is negative, suggesting distribution or selling pressure. Our AI-powered investment score rates FOLD at 59.7/100 with a HOLD recommendation.

FOLD Technical Chart
  • Candlesticks: Green = price up, Red = price down. Body shows open/close, wicks show high/low.
  • SMAs: Moving averages help identify trends. Price above SMA = bullish, below = bearish.
  • Options OI: Shows max open interest strikes. High OI = significant price levels.
  • Volume Profile: Shows price levels with most trading activity. POC = Point of Control (highest volume).
  • Earnings: Vertical lines mark earnings dates. Watch for volatility around these dates.
  • Gamma Walls: Key support/resistance from options gamma exposure. Orange = resistance above, Purple = support below.
  • Fibonacci Retracement: Auto-calculated support/resistance levels based on recent high/low. Key levels: 23.6%, 38.2%, 50%, 61.8%, 78.6%.
  • Unusual Activity: Highlights days with abnormal volume (2x+ average) or large price moves (5%+). Red marker = unusual activity detected.
Technical Indicators

Select indicators above to analyze technical patterns

Indicators will appear below the price chart with perfectly aligned dates

Volume Profile Analysis

Horizontal histogram showing volume distribution at each price level with buying/selling pressure

FOLD Price vs Max Options Open Interest
FOLD Max Change In Options Open Interest

FOLD Options - Sort by Max open Interest (near term)

21st May 2026 (Data is delayed in normal mkt. hours)

Type Expiration Strike OI Change in
OI		 Volume Ask PC Delta Vega Volatility % change Track

FOLD Daily Out of Money Options - Sort by Max open Interest (near term)

21st May 2026 (Data is delayed in normal mkt. hours)

Type Expiration Strike OI Change in
OI		 Volume Ask PC Delta Vega Volatility % change Track

FOLD Daily In the Money Options - Sort by Max open Interest (near term)

21st May 2026 (Data is delayed in normal mkt. hours)

Type Expiration Strike OI Change in
OI		 Volume Ask PC Delta Vega Volatility % change Track

FOLD Most Active Options by Volume(near term)

21st May 2026 (Data is delayed in normal mkt. hours)

Type Expiration Strike Volume OI Change in
OI		 Ask PC Delta Vega Volatility % change Track

Amicus Therapeutics, Inc is not trading above both 50 Day and 200 Day SMA which is considered Bearish.

FOLD Moving Averages Analysis

FOLD (Amicus Therapeutics, Inc) Simple Moving Averages

Moving Averages are last updated

Days MA

FOLD Fundamental Analysis

P/E (Forward) 30.4878
P/E (Trailing) --
Market Cap ($) 4.5 billion
Earnings/Share ($) -0.09
Net Proft Margin (%) -0.0428
Dividend/Share ($) --
EPS Estimate Current Year ($) 0.0726
EPS Estimate Next Year ($) 0.8189
WallStreet Target Price ($) 14.5
Most Recent Quarter